NCT05834335|Completed
Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment
PASCOMS
Loading search results
PASCOMS
Sponsor study identifier
observational
400
1 country
1
Study Start
March 1, 2020
Actual (reported)Primary Completion
December 1, 2022
Actual (reported)Study Completion
April 1, 2023
Actual (reported)The investigators will conduct retrospective observational cohort study at the Nationaal Multiple Sclerose Centrum (NMSC) Melsbroek (Belgium), which is a large center specifically focusing on neurological management, multidisciplinary care and/or rehabilitation in patients with MS. Primary endpoint For each DMT category, as defined above, the proportion of patients with a worse COVID-19 outcome (i.e., hospitalization and/or death) will be compared between those 'protected' versus 'unprotected' by vaccination at the time of SARS-CoV-2 infection. Corrections will be applied for any eventual imbalance in demographics, potentially relevant to COVID-19 outcome, between subgroups that are compared to each other, if indicated/feasible.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 1, 2023
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 1, 2020
Actual (reported)December 1, 2022
Actual (reported)April 1, 2023
Actual (reported)April 17, 2023
Actual (reported)April 28, 2023
Actual (reported)For each DMT category the proportion of patients with a worse COVID-19 outcome will be compared between those 'protected' versus 'unprotected' by vaccination at the time of SARS-CoV-2 infection.
1 year
Patients with multiple sclerosis and a positive selftest or positive PCR test for Corona disease
Nationaal MS center
Melsbroek, Vlaams Brabant, 1820, Belgium
400 participants (actual enrollment reported by the registry).
First Submitted
April 17, 2023
First Posted
April 28, 2023
Study Start
March 1, 2020
Actual (reported)Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
Contact the study team to confirm eligibility.
Primary Completion
December 1, 2022
Actual (reported)Study Completion
April 1, 2023
Actual (reported)Last Updated
November 18, 2023
Record last verified: 2023-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: